Pancreatic Cancer Research

ResearcherHarvard UniversityNo recent work listed

Alan Paul Venook

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9749-6548; OpenAlex author ID A5037875642. Sources: ClinicalTrials.gov.

Their work

Papers
9 (first author 0, last author 2)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
54
Papers, trials and grants by year

2011: 1 trial · 2012: 1 paper · 2013: 2 papers · 2014: 1 paper · 2015: none · 2016: 3 papers · 2017: none · 2018: 1 paper · 2019: none · 2020: 1 paper

Papers 9

  1. Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer. Co-author DOI 10.1016/j.ymthe.2020.07.017↗
  2. The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation. Co-author DOI 10.1371/journal.pone.0202272↗
  3. Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Tri… Last author DOI 10.1001/jamasurg.2016.1137↗
  4. A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000458↗
  5. A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-15-0979↗
  6. 25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance). Last author DOI 10.1093/jnci/dju185↗
  7. Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Co-author DOI 10.1158/1078-0432.ccr-13-0926↗
  8. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Co-author DOI 10.1245/s10434-013-2886-9↗
  9. Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 8030… Co-author DOI 10.1002/cncr.26270↗

Trials 1

  1. Relationship Between Vitamin D Biomarkers and Survival in Blood Samples From Patients With Advanced Pancreatic Cancer Principal investigator NCT01327794↗

Closest collaborators

The 25 strongest of 54 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hedy Lee Kindler · 7 shared papers, 2012–2018 · strength 0.29
  2. Andrew H. Ko · 3 shared papers, 2016–2020 · strength 0.19
  3. Margaret A. Tempero · 3 shared papers, 2016–2020 · strength 0.19
  4. Kouros Owzar · 3 shared papers, 2012–2018 · strength 0.13
  5. Chen Jiang · 3 shared papers, 2012–2018 · strength 0.13
  6. Marina Talamonti · 2 shared papers, 2016–2018 · strength 0.10
  7. Federico Innocenti · 2 shared papers, 2014–2018 · strength 0.10
  8. Katherine Van Loon · 2 shared papers, 2014–2018 · strength 0.10
  9. Noelle K. LoConte · 2 shared papers, 2016 · strength 0.10
  10. Lawrence H. Fong · 1 shared paper, 2020 · strength 0.09
  11. Carl H. June · 1 shared paper, 2020 · strength 0.09
  12. Gabriela Plesa · 1 shared paper, 2020 · strength 0.09
  13. Gregory Lawrence Beatty · 1 shared paper, 2020 · strength 0.09
  14. Mark H. O’Hara · 1 shared paper, 2020 · strength 0.09
  15. Tanios Bekaii‐Saab · 2 shared papers, 2016 · strength 0.09
  16. Matthew H. G. Katz · 2 shared papers, 2013–2016 · strength 0.08
  17. Syed Ameen Ahmad · 2 shared papers, 2013–2016 · strength 0.08
  18. Joseph M. Herman · 2 shared papers, 2013–2016 · strength 0.08
  19. Robert Marsh · 2 shared papers, 2013–2016 · strength 0.08
  20. Andrew M. Lowy · 2 shared papers, 2013–2016 · strength 0.08
  21. Philip A. Philip · 2 shared papers, 2013–2016 · strength 0.08
  22. Eileen Mary O'Reilly · 2 shared papers, 2012–2014 · strength 0.07
  23. Richard M. Goldberg · 2 shared papers, 2012–2013 · strength 0.07
  24. Nicole F. Neel · 1 shared paper, 2018 · strength 0.06
  25. Mark J. Ratain · 1 shared paper, 2018 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.